Maris, Nico A <br/><br/>
Salmeterol enhances pulmonary fibrinolysis in healthy volunteers.  [electronic resource] 

 -  Critical care medicine  Jan 2007 
 - 57-63 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0090-3493 
<br/><br/><label>Standard No.: </label>10.1097/01.CCM.0000249827.29387.4E  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Inhalation<br/>Adrenergic beta-Agonists--pharmacology<br/>Adult<br/>Albuterol--analogs & derivatives<br/>Analysis of Variance<br/>Bronchoalveolar Lavage Fluid--chemistry<br/>Bronchodilator Agents--pharmacology<br/>Factor VIIa--analysis<br/>Fibrinolysis--drug effects<br/>Humans<br/>Inflammation<br/>Lipopolysaccharides--adverse effects<br/>Lung--drug effects<br/>Lung Diseases--drug therapy<br/>Macrophages, Alveolar--drug effects<br/>Male<br/>Plasminogen Activator Inhibitor 1--analysis<br/>Plasminogen Activators--analysis<br/>Protein C--analysis<br/>Salmeterol Xinafoate<br/>Single-Blind Method<br/>Thrombomodulin--analysis<br/>Thromboplastin--analysis<br/>Tissue Plasminogen Activator--analysis<br/>Urokinase-Type Plasminogen Activator--analysis